| Overview |
| bs-22472R-HRP |
| RNF105 Polyclonal Antibody, HRP Conjugated |
| IHC-P |
| Mouse, Rat |
| Human |
| Specifications |
| HRP |
| Rabbit |
| KLH conjugated synthetic peptide derived from human RNF105 |
| 251-350/2025 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 7267 |
| P53804 |
| Nucleus |
| DCRR1; E3 ubiquitin protein ligase TTC3; E3 ubiquitin-protein ligase TTC3; Protein DCRR1; RING finger protein 105;Tetratricopeptide repeat protein 3 (TPR repeat protein D); Tetratricopeptide repeat protein 3; TPR repeat protein 3; TPR repeat protein D; TPRD; TPRDI; TPRDII; TPRDIII; TTC3; TTC3_HUMAN. |
| E3 ubiquitin-protein ligase that mediates the ubiquitination and subsequent degradation of phosphorylated Akt (AKT1, AKT2 and AKT3) in the nucleus. Acts as a terminal regulator of Akt signaling after activation; its phosphorylation by Akt, which is a prerequisite for ubiquitin ligase activity, suggests the existence of a regulation mechanism required to control Akt levels after activation. Catalyzes the formation of 'Lys-48'-polyubiquitin chains. May play a role in neuronal differentiation inhibition via its interaction with CIT. |
| Application Dilution |
| IHC-P |
1:200-400 |
Powered by Bioz